宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

02659 宝济药业-B

休市中 12-19 16:08:04

73.000

+0.500

+0.69%

最高75.000	最低71.800	成交量56.00万
今开72.600	昨收72.500	日振幅4.41%
总市值237.97亿	流通市值112.42亿	总股本3.26亿
成交额4,093万	换手率0.36%	流通股本1.54亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"宝济药业-B","latestPrice":73,"timestamp":1766131684652,"preClose":72.5,"halted":0,"volume":560000,"delay":0,"floatShares":154000000,"shares":325981465,"eps":0,"marketStatus":"休市中","change":0.5,"latestTime":"12-19 16:08:04","open":72.6,"high":75,"low":71.8,"amount":40934410,"amplitude":0.044138,"askPrice":73.05,"askSize":100,"bidPrice":73,"bidSize":200,"shortable":0,"etf":0,"ttmEps":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1766367000000},"marketStatusCode":7,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":72.5,"openAndCloseTimeList":[[1766107800000,1766116800000],[1766120400000,1766131200000]],"volumeRatio":0.776797,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/02659","defaultTab":"news","newsList":[{"id":"2592154232","title":"宝济药业-B12月19日获主力加仓147.1万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2592154232","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592154232?lang=zh_cn&edition=full","pubTime":"2025-12-19 16:15","pubTimestamp":1766132151,"startTime":"0","endTime":"0","summary":"12月19日, 宝济药业-B股价涨0.69%，报收73.00元，成交金额4093.4万元，换手率0.36%，振幅4.41%，量比0.77。宝济药业-B今日主力资金净流入147.1万元，连续4日净流入，上一交易日主力净流入685.0万元。该股近5个交易日上涨6.80%，主力资金累计净流入1295.0万元；近20日主力资金累计净流入1874.3万元，其中净流入天数为6日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162059a45f244e&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251219162059a45f244e&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2591026826","title":"宝济药业-B12月16日主力净流入155.4万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2591026826","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591026826?lang=zh_cn&edition=full","pubTime":"2025-12-16 16:16","pubTimestamp":1765872960,"startTime":"0","endTime":"0","summary":"12月16日, 宝济药业-B股价涨1.59%，报收67.00元，成交金额3705.1万元，换手率0.36%，振幅5.16%，量比0.00。宝济药业-B今日主力资金净流入155.4万元，上一交易日主力净流出15.6万元。该股近5个交易日上涨153.98%，主力资金累计净流入719.1万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入719.1万元，其中净流入天数为3日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162249a4519163&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251216162249a4519163&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":1},{"id":"2591616778","title":"宝济药业-B12月15日主力净流出15.6万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2591616778","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591616778?lang=zh_cn&edition=full","pubTime":"2025-12-15 16:15","pubTimestamp":1765786536,"startTime":"0","endTime":"0","summary":"12月15日, 宝济药业-B股价跌3.51%，报收65.95元，成交金额5059.6万元，换手率0.50%，振幅6.14%，量比0.00。宝济药业-B今日主力资金净流出15.6万元，上一交易日主力净流入13.1万元。该股近5个交易日上涨148.67%，主力资金累计净流入563.7万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入563.7万元，其中净流入天数为2日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161815a44d2d53&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251215161815a44d2d53&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2590519099","title":"交银国际作为联席全球协调人助力宝济药业完成港股IPO项目","url":"https://stock-news.laohu8.com/highlight/detail?id=2590519099","media":"交银国际","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590519099?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:41","pubTimestamp":1765460485,"startTime":"0","endTime":"0","summary":"宝济药业本次全球发售定价每股26.38港元，发行37,911,700股H股，融资规模约为10.00亿港元。交银国际担任联席全球协调人、联席账簿管理人兼联席牵头经办人，全程高效助力宝济药业顺利登陆港股资本市场。宝济药业已布局多个治疗领域的自主管线，拥有12款自主开发的在研和上市产品。通过将稳健的生产体系与前瞻性的研发能力深度融合，宝济药业已形成“创新研发—生物制造—临床转化”一体化的全产业链布局。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211214729a699b2f3&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1147","02659","03329"],"gpt_icon":1},{"id":"2590659546","title":"宝济药业-B12月11日主力净流入566.1万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2590659546","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590659546?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:15","pubTimestamp":1765440949,"startTime":"0","endTime":"0","summary":"12月11日, 宝济药业-B股价涨9.52%，报收69.00元，成交金额1.4亿元，换手率1.43%，振幅13.10%，量比0.00。该股近5个交易日上涨165.35%，主力资金累计净流入566.1万元；近20日主力资金累计净流入566.1万元，其中净流入天数为1日。该股主力净额占比0.05%，港股市场排名89/2692。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162037a441f3a4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251211162037a441f3a4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2590557916","title":"“自我造血”的新晋18A，宝济药业-B(02659)以“三驾马车”打造可持续增长样本","url":"https://stock-news.laohu8.com/highlight/detail?id=2590557916","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590557916?lang=zh_cn&edition=full","pubTime":"2025-12-11 09:08","pubTimestamp":1765415296,"startTime":"0","endTime":"0","summary":"在这一背景下，宝济药业-B凭借与众不同的三驾“马车”，开辟了一条独特的差异化赛道，为行业提供了一种全新的Biotech生存逻辑与创新范式。这种由技术升级带来的高质量和高安全性，正是宝济药业在市场上实现“技术替代”红利的核心保障。目前，宝济药业已建成和在建的生产基地总占地面积近10万平方米，预计反应器总容积将达到约26,100L，年产能预计可达2250万份制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1380193.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659"],"gpt_icon":1},{"id":"2590393379","title":"宝济药业-B(02659)捐款100万港元驰援香港大埔火灾 全力支持救灾重建工作","url":"https://stock-news.laohu8.com/highlight/detail?id=2590393379","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590393379?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:46","pubTimestamp":1765331195,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，11月26日，香港大埔宏福苑多栋住宅楼发生火灾，造成重大人员伤亡，灾情牵动着社会各界的心。值此艰难时刻，为帮助受灾同胞渡过难关，宝济药业-B(02659)积极履行企业社会责任，宣布捐款100万港元，用于受灾居民的紧急救援、生活物资补给、医疗救助及后续重建工作。宝济药业向遇难者及其家属表示沉痛哀悼，并向所有奋不顾身投入救援的消防及救护人员，以及第一时间响应的前线团队致以崇高敬意，感谢他们在危难关头展现的专业精神与无私付出。宝济药业将继续密切关注救灾进展，期盼在社会各界同心同力的援助下，社区早日恢复秩序，市民重归平安生活。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379689.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659"],"gpt_icon":0},{"id":"1175227784","title":"异动解读 | 新股宝济药业-B(02659)首日盘中飙涨120.81%，公开发售超购3526倍引爆市场热情","url":"https://stock-news.laohu8.com/highlight/detail?id=1175227784","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1175227784?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:33","pubTimestamp":1765330391,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨120.81%，创下港股新股首日交易的亮眼表现。消息面上，宝济药业-B此次IPO获得市场狂热追捧，香港公开发售部分超额认购达3526.34倍，国际配售部分也获6.59倍认购。宝济药业是一家临床及商业化阶段的生物技术公司，专注于合成生物技术开发重组生物药物。公司2025年上半年收入同比大增2716%，展现出强劲的商业化潜力。","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"gpt_icon":0},{"id":"1167510070","title":"上海宝济药业-B在香港首日以每股60.5港元开盘，较发行价每股26.38港元大幅上涨","url":"https://stock-news.laohu8.com/highlight/detail?id=1167510070","media":"美股速递","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1167510070?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:22","pubTimestamp":1765329779,"startTime":"0","endTime":"0","summary":"上海宝济药业-B在香港首日的开盘价定为每股60.5港元，相较于发行价每股26.38港元大幅上涨。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"gpt_icon":0},{"id":"1170105562","title":"港股开盘 | 恒指平开，科指低开0.04%！宝济药业-B首挂飙涨近130%","url":"https://stock-news.laohu8.com/highlight/detail?id=1170105562","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1170105562?lang=zh_cn&edition=full","pubTime":"2025-12-10 09:20","pubTimestamp":1765329630,"startTime":"0","endTime":"0","summary":"12月10日，恒生指数开盘上涨1.26点，涨幅0.0%，报25435.49点；恒生科技指数开盘下跌2.33点，跌幅0.04%，报5552.35点；国企指数开盘上涨0.46点，涨幅0.01%，报8936.87点；红筹指数开盘上涨14.33点，涨幅0.35%，报4144.82点。贵金属板块普涨，中国白银集团涨超7%，赤峰黄金涨近2%，招金矿业、、山东黄金、紫金黄金国际涨超1%；长飞光纤光缆跌超3%，拟折让约14.93%配售合共7000万股配售股份，净筹约22.29亿港元；宝济药业-B首挂飙涨近130%，此前公开发售获得3526.34倍认购，一手中签率7%。","market":"hk","thumbnail":"https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/c1cb237e736a4e03c939622e7b71e8e7"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659","HSI","HSTECH"],"gpt_icon":0},{"id":"2590344140","title":"宝济药业-B(02659.HK)香港IPO发行价定为每股26.38港元 净筹9.2亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2590344140","media":"格隆汇","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590344140?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:09","pubTimestamp":1765289380,"startTime":"0","endTime":"0","summary":"格隆汇12月9日丨宝济药业-B公告，公司全球发售37,911,700股H股，每股H股26.38港元，所得款项净额9.2亿港元。香港公开发售股份数目占全球发售股份数目10%，获认购3,526.34倍；国际发售股份数目占全球发售股份90%，获认购6.59倍。假设全球发售于2025年12月10日(星期三)上午八时正或前成为无条件，预期H股将于2025年12月10日(星期三)上午九时正开始在联交所买卖。H股将以100股H股为一手买卖单位进行交易，H股的股份代号为2659。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2025/12/09220954656574.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["02659"],"gpt_icon":0},{"id":"2590234961","title":"沸腾！暗盘，暴涨超113%！","url":"https://stock-news.laohu8.com/highlight/detail?id=2590234961","media":"券商中国","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590234961?lang=zh_cn&edition=full","pubTime":"2025-12-09 20:58","pubTimestamp":1765285080,"startTime":"0","endTime":"0","summary":"　　今日，港股新股宝济药业-B股价在暗盘交易中一度暴涨超115%，以每手100股计算，若不计手续费，每手可赚3057港元。　　据悉，宝济药业-B于12月2日至5日招股，市场统计数据显示，截至12月5日，宝济药业-B获券商借出2692.1亿港元孖展，以公开发售集资额1亿港元计算，超购2690.8倍。　　12月9日，宝济药业-B股价在暗盘交易中表现强劲，一度暴涨超115%，截至暗盘收盘，报56港元，较招股价大涨112.28%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/zqgd/2025-12-09/doc-inhaffac0778007.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["02659"],"gpt_icon":1},{"id":"1102812015","title":"老虎暗盘 | 宝济药业-B涨超100%，中签一手赚超2700港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1102812015","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1102812015?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:15","pubTimestamp":1765268153,"startTime":"0","endTime":"0","summary":"12月9日，宝济药业-B暗盘涨超100%，总市值超176亿港元。宝济药业的药物开发专注于高效优化具有重大市场价值或未开发商机的经验证疗法，这使公司在生物制药行业脱颖而出。通过升级已在临床实现广泛采用的现有疗法，宝济药业确保公司的创新可直接造福既有及不断扩大的患者群体。宝济药业的产品管线旨在通过公司的合成生物技术能力，着力攻克该等产品的关键限制，将开发重点与真实的临床需求紧密联系。","market":"us","thumbnail":"https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/85675909dc6c67ee0181339c18bcfdff"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"0f289a0c0f19ee2212a31014a11a9f2a","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"gpt_icon":0},{"id":"2589388521","title":"新股消息 | 超购2690.8倍！宝济药业-B招股结束，孖展认购额录得2692亿港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2589388521","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589388521?lang=zh_cn&edition=full","pubTime":"2025-12-08 10:40","pubTimestamp":1765161608,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，生物技术公司宝济药业-B(02659)12月2日至5日招股，最新已经结束认购，预期将于12月10日挂牌买卖。市场统计数据显示，截至上周五(12月5日)，宝济药业获券商借出2692.1亿港元孖展，以公开发售集资额1亿港元计，超购2690.8倍。根据发行计划，宝济药业计划发行3791.2万股H股，一成于香港作公开发售，发售价为每股26.38港元，集资10亿港元。每手100股，一手入场费2664.6港元。中信证券、海通国际为联席保荐人。宝济药业引入安科生物香港、DC Alpha SPC及国泰君安证券投资(有关中和场外掉期)为基石投资者，投资金额2亿港元。","market":"hk","thumbnail":"https://static.tigerbbs.com/266ab84342c6ca65b538d0b42bc1dc4e","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/266ab84342c6ca65b538d0b42bc1dc4e"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6b0137894d2991d948d02a4717134c34","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378634.html","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"2","news_top_title":"新股消息 | 宝济药业-B(02659)招股结束 孖展认购额录得2692.1亿港元 超购2690.8倍","news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02659"],"gpt_icon":0},{"id":"2589865213","title":"ADC与PD-1红海之外，宝济药业如何找到生物医药的“第二增长曲线”？","url":"https://stock-news.laohu8.com/highlight/detail?id=2589865213","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589865213?lang=zh_cn&edition=full","pubTime":"2025-12-05 13:33","pubTimestamp":1764912788,"startTime":"0","endTime":"0","summary":"而在ADC、PD-1等热门靶点赛道数百家企业拥挤厮杀，从临床入组速度到未来的市场定价无不白热化的竞争中，上海宝济药业股份有限公司选择了一条截然不同的差异化战略路径。与传统疗法相比，KJ103的革命性优势则在于其“快”。目前，其领先地位和临床价值已获得监管机构的高度认可。对于KJ017而言，其市场空间并不取决于自身的销量，而是与整个千亿级生物药市场的增长深度绑定，其商业模式堪称典型的“卖水人”逻辑。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1378061.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["ADC","LU1169589451.USD","02659","161726","399441","PD","BK4231","LU1169590202.USD","BK4023","BK4080"],"gpt_icon":1},{"id":"2589530078","title":"【看新股】港股IPO月度透视：11月IPO募资超406亿港元 赛力斯、小马智行募资额居前","url":"https://stock-news.laohu8.com/highlight/detail?id=2589530078","media":"面包财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2589530078?lang=zh_cn&edition=full","pubTime":"2025-12-05 07:30","pubTimestamp":1764891000,"startTime":"0","endTime":"0","summary":"其中，赛力斯、小马智行首发募集总额居前，分别达142.83亿港元、67.07亿港元。截至2025年11月30日，港股IPO排队企业总共306家，其中有14家企业已通过聆讯。11月有11只新股上市2025年11月，港交所共有11只新股上市，合计募资总额达406.09亿港元，较10月上市募资规模增超三成。此外，创新实业、中伟新材、均胜电子募资超过30亿港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205073138a4cd6e93&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251205073138a4cd6e93&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1119","02026","02659","09927","02539","02693","02788","BK1109"],"gpt_icon":1},{"id":"2588004157","title":"创新药重回港股牌桌：已有1款新药上市的宝济药业(02659)启动招股","url":"https://stock-news.laohu8.com/highlight/detail?id=2588004157","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588004157?lang=zh_cn&edition=full","pubTime":"2025-12-04 16:27","pubTimestamp":1764836842,"startTime":"0","endTime":"0","summary":"公开数据显示，今年截止12月3日，在港上市的13家18A公司，共募资额超过260亿港元。即将在港IPO的18A公司宝济药业创始人刘彦君于近期对腾讯新闻《潜望》表示。今年在港IPO的13家18A公司，包括宝济药业、中慧生物、劲方生物等，上市之前即有一款新药获批得上市。在此之前的绝大多数18A公司在港挂牌时，都未曾获得药监局的新药上市审批。这也可能是港股今年最后一家IPO的18A公司。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1377671.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","06978","02659","159992","BK1161"],"gpt_icon":0},{"id":"2588062764","title":"500亿元风口起航！宝济药业IPO聆讯过关，商业化之弓拉满","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062764","media":"医药研究社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588062764?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:38","pubTimestamp":1764682734,"startTime":"0","endTime":"0","summary":"产品商业化的大幕悄然拉开。尤其引人关注的是，此次宝济药业通过聆讯，踩在了一个微妙的节奏点上——公司核心产品的商业化近了。在500亿元赛道上，找准优势区间从战略聚焦来看，宝济药业的盘子铺得不算小。目前可以确定的是，宝济药业做好了商业化准备。与此同时，宝济药业的手头资金不算微薄，截至2025年6月，公司账上仍有4.53亿元现金，推进进度领先管线的商业化应该绰绰有余。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203010501a71fa002&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203010501a71fa002&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2588706276","title":"宝济药业新股简介","url":"https://stock-news.laohu8.com/highlight/detail?id=2588706276","media":"真灼财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588706276?lang=zh_cn&edition=full","pubTime":"2025-12-02 21:29","pubTimestamp":1764682175,"startTime":"0","endTime":"0","summary":"宝济药业是一家于 2019 年成立的生物技术公司，战略性聚焦四大领域： 大容量皮下给药， 抗体介导的自身免疫性疾病， 辅助生殖；及  重组生物制药。目前最接近商业化的药物分别为 SJ02 及 KJ017。KJ017 是中国首个及唯一一个进入 NDA 阶段的重组人透明质酸酶，针对大容量皮下注射的需求，宝济药业可抢占先机。宝济药业引入 3 位基石投资者，合共认购 20% 的发售股份数。宝济药业招股价为 26.38 港元 / 股，对应总市值为 86 亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203012033a4c8846a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251203012033a4c8846a&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0},{"id":"2588062760","title":"安科生物1.12亿港元基石投资宝济药业港股IPO，深化辅助生殖领域协同合作","url":"https://stock-news.laohu8.com/highlight/detail?id=2588062760","media":"动脉网","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2588062760?lang=zh_cn&edition=full","pubTime":"2025-12-02 18:31","pubTimestamp":1764671460,"startTime":"0","endTime":"0","summary":"2025年12月2日，安科生物全资子公司安科生物（香港）拟用1.12亿港元自筹资金，作为基石投资者参与宝济药业港股IPO，并签署《基石投资协议》，具体持股比例依宝济药业最终发行市值确定。宝济药业是专注合成生物技术重组生物药物的生物技术公司，有12款在研产品，其中三款核心产品处于不同阶段。今年7月安科生物已获晟诺娃®中国境内独家销售权，11月该产品推向市场。安科生物在生物制药领域经验丰富，此次基石投资将深化与宝济药业合作，完善辅助生殖产品矩阵，加速长效FSH-CTP产品布局，未来双方将继续拓展在辅助生殖及其他生物医药领域布局。文中未提及投资机构、财务顾问及融资目的相关特定指向内容。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202190612a71f1103&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251202190612a71f1103&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02659"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.baopharma.com","stockEarnings":[{"period":"1week","weight":0.068},{"period":"1month","weight":1.7672},{"period":"ytd","weight":1.7672}],"compareEarnings":[{"period":"1week","weight":-0.011},{"period":"1month","weight":-0.0054},{"period":"3month","weight":-0.0322},{"period":"6month","weight":0.0918},{"period":"1year","weight":0.3006},{"period":"ytd","weight":0.2807}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"上海宝济药业股份有限公司专注于重组蛋白药物和抗体药物的产业化与商业化。我们在上海建设了符合cGMP标准的生产基地，占地约63,000平方米，规划了多条覆盖哺乳动物细胞表达系统及大肠杆菌/酵母表达系统的原液生产线，以及水针剂、冻干粉针剂和一次性预灌封制剂的成品生产线。","exchange":"SEHK","name":"宝济药业-B","nameEN":"BAO PHARMA-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宝济药业-B,02659,宝济药业-B股票,宝济药业-B股票老虎,宝济药业-B股票老虎国际,宝济药业-B行情,宝济药业-B股票行情,宝济药业-B股价,宝济药业-B股市,宝济药业-B股票价格,宝济药业-B股票交易,宝济药业-B股票购买,宝济药业-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宝济药业-B(02659)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宝济药业-B(02659)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}